Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
- Conditions
- Tuberculous Meningitis
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 330
- Registration Number
- NCT05383742
- Locations
- 🇵🇪
Socios en Salud Sucursal Peru CRS (Site ID: 31985), Lima, Peru
🇵🇪Barranco CRS (Site ID:11301), Lima, Peru
🇵🇭TB HIV Innovations and Clinical Research Foundation Corp (Site ID: 31981), Cavite, Philippines
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- Conditions
- Tuberculosis, Multidrug-Resistant
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 212
- Registration Number
- NCT05306223
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China
🇨🇳The Eighth Medical Center of PLA General Hospital, Beijing, China
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Tuberculosis Research Centre, India
- Target Recruit Count
- 550
- Registration Number
- NCT05047055
- Locations
- 🇮🇳
National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
- Conditions
- TuberculosisPulmonary TuberculosisHIV Coinfection
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 112
- Registration Number
- NCT04930744
- Locations
- 🇿🇦
Tembisa Clinical Research Centre-The Aurum Institute, Johannesburg, Gauteng, South Africa
🇿🇦Isango Lethemba TB Research Unit, Port Elizabeth, South Africa
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
- Conditions
- Multidrug Resistant Tuberculosis
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT04717908
- Locations
- 🇨🇳
The Third People's Hospital of Shenzhen City, Shenzhen, Guangzhou, China
🇨🇳The Central Hospital of Wenzhou City, Wenzhou, Zhejiang, China
🇨🇳Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital), Ningbo, Zhejiang, China
Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University Hospital, Linkoeping
- Target Recruit Count
- 40
- Registration Number
- NCT04694586
- Locations
- 🇸🇪
Linköping University Hospital, Linköping, Sweden
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 22
- Registration Number
- NCT04629378
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 154
- Registration Number
- NCT04504851
- Locations
- 🇺🇬
Joint Clinical Research Centre, Kampala, Uganda
🇻🇳Vietnam Military Medical University, Hanoi, Vietnam
🇵🇭Tropical Disease Foundation, Makati City, Philippines
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 926
- Registration Number
- NCT04485156
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.